EMA Recommends Extension of Indications for Inotuzumab Ozogamicin By Ogkologos - April 29, 2026 77 0 Facebook Twitter Google+ Pinterest WhatsApp New indication concerns treatment of paediatric patients with CD22-positive B cell precursor ALL Source RELATED ARTICLESMORE FROM AUTHOR New Targeted Therapy Shows Promising Early Results in Advanced Pancreatic Cancer FDA Approves Pivekimab Sunirine-pvzy for Blastic Plasmacytoid Dendritic Cell Neoplasm, an Ultra-Rare Haematologic Malignancy Ivonescimab Plus Chemotherapy Improves OS Compared with Tislelizumab Plus Chemotherapy in Previously Untreated Patients with Advanced Squamous NSCLC MOST POPULAR Lorlatinib in First-Line Treatment of Patients with Advanced ALK-Positive NSCLC With... May 30, 2022 Subcutaneous Daratumumab Monotherapy for Patients with High-Risk Smoldering Multiple Myeloma December 18, 2024 FDA Approves Sotorasib with Panitumumab for KRAS G12C-mutated Colorectal Cancer February 13, 2025 Tackling under-representation of Black data scientists in cancer research November 7, 2022 Load more HOT NEWS Exceptional Response to Single-Agent Anti-PD1 Therapy Observed in Patients with Advanced... Qué debo saber sobre los programas de emparejamiento de ensayos clínicos... ESMO Breast Cancer Virtual Congress 2021, 5-8 May CancerLand Bookshelf : Loosen
